Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
The deal positions Crescent to test a Kelun ADC in combination with its PD-1xVEGF bispecific.
Nick Paul Taylor
Dec 4, 2025 9:50am
ADC biotech raises $120M to seek best-in-class formula
Nov 17, 2025 8:00am
Day One pens $285M deal for Mersana
Nov 13, 2025 10:15am
Merck bags $700M from Blackstone, spends $150M to regain asset
Nov 4, 2025 9:15am
Neok exits stealth with $75M to take bispecific ADCs into clinic
Nov 4, 2025 7:00am
GSK pens $357M pact with French biotech for prostate cancer ADC
Oct 27, 2025 4:07am
